The public health community, the provider community, and the general public need to help the pharmaceutical industry increase access to services and put downward pressure on costs, said Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health.
The public health community, the provider community, and the general public need to help the pharmaceutical industry increase access to services and put downward pressure on costs, said Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health.
Transcript (slightly modified)
What impact could the recent spotlight from patients, lawmakers, and even the president, have on the price of pharmaceuticals?
I think what the pharmaceutical industry needs is some way to get the quantity up. Right now, they don’t have any mechanisms because they really can’t do very much.
I think the public health community, the provider community, and the general public, needs to do something to help the pharmaceutical industry to get their quantity up. They’re modeling their assumptions that only 10% to 15% of the population is going to get a particular drug and that is how they have generated their revenue estimates. So, if we can just make it that they get the same revenue, but with 60% to 80% of the people getting that same drug, we are all better off—but right now we can’t do it.
So, I think that the idea for me, is to improve access to care by helping the pharmaceutical industry increase the access to services.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen